Arcus Biosciences - RCUS Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RCUS shares.
View RCUS analyst ratings or view top-rated stocks.

9 brokerages have issued 12 month price targets for Arcus Biosciences' shares. Their RCUS share price forecasts range from $33.00 to $51.00. On average, they predict the company's stock price to reach $41.33 in the next twelve months. This suggests a possible upside of 126.6% from the stock's current price.
View analysts price targets for RCUS or view top-rated stocks among Wall Street analysts.

Arcus Biosciences' stock was trading at $20.68 at the beginning of the year. Since then, RCUS stock has decreased by 11.8% and is now trading at $18.24.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our RCUS earnings forecast.

Arcus Biosciences, Inc. (NYSE:RCUS) released its quarterly earnings results on Monday, November, 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.13) by $0.02. The firm had revenue of $9.46 million for the quarter, compared to analysts' expectations of $9.27 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 36.77% and a negative net margin of 237.26%. During the same period in the prior year, the company posted $0.03 earnings per share.

ETFs with the largest weight of Arcus Biosciences (NYSE:RCUS) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), First Trust Innovation Leaders ETF (ILDR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).

4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD).

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RCUS stock can currently be purchased for approximately $18.24.

Arcus Biosciences (NYSE:RCUS) has a market capitalization of $1.33 billion and generates $112 million in revenue each year. The company earns $-267,000,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis.

The company employs 366 workers across the globe.

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for the company is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com.